
The Damani playbook: How a reclusive investor built a Rs 2 lakh crore empire
In an era of algorithmic trading, social media hype, and startup billionaires, Damani has quietly built a Rs 2 lakh crore fortune rooted in an old-school philosophy: buy great businesses at fair prices, stay patient, and never compromise on quality.
He began as a stock trader in the 1980s, made significant profits by short-selling during the Harshad Mehta bubble, and then transitioned into a long-term value investor who spotted enduring winners in companies like VST Industries, Gillette, and CRISIL.
But his most iconic move came when he stepped beyond investing to build DMart, a no-frills, cash-generating retail chain that now defines how middle-class India shops.
We look at the Damani blueprint: What allowed him to see value in cigarettes and cement while others looked away? How did his investment philosophy shape how DMart was built, run, and scaled up? And what does his track record teach retail investors about conviction, concentration, and compounding?
The first bets: What Damani saw that others missed
To understand how Damani began buying stocks and why those stocks became multibaggers, you have to first understand what the Indian stock market looked like in the mid-1990s.
The aftershocks of the 1992 Harshad Mehta scam had shaken investor confidence. IPO booms had soured into penny stock busts. Foreign institutional investors were just beginning to test Indian waters, and retail investors were swinging between thrill and trauma.
Momentum stocks, steel, cement, infra, and PSUs were the flavour of the season. The market loved stories, not numbers. Stock prices moved on rumour, not results.
In the middle of this chaos, Damani made a counterintuitive choice: he started buying FMCG stocks.
Gillette. Colgate. HUL. Nestlé
In a noisy market obsessed with 'fast money,' Damani was already thinking in terms of steady compounding. He wasn't looking for stocks that could double in 6 months, but he was looking for businesses that wouldn't lose money in 10 years.
At the time, large consumer companies were viewed as boring. Safe, yes. But slow. Their earnings were predictable, margins stable, but growth wasn't exciting. They rarely made headlines — and rarely attracted traders.
But to Damani, that was the whole point.
These were high-quality franchises with:
Brand monopolies (Gillette had over 70% of the shaving market)
High gross margins and low capital intensity
Cash flows that exceeded capex every single year
And most importantly, pricing power — the ability to pass on inflation without losing customers
They also had deep distribution systems, owned by multinationals, and led by professionally run, non-promoter management. In a market full of promoter-led companies with opaque accounting and debt-fuelled growth, Damani found comfort in governance and stability.
And he understood something that few retail investors did then: India's middle class was expanding. Slowly, yes, but structurally. Urbanisation, consumer credit, and lifestyle upgrades were beginning to shape demand in categories like toothpaste, shampoo, razors, and packaged food.
So while the market obsessed over cyclical sugar stocks or speculative infra plays, Damani quietly bought consumer staples at sensible valuations, content with 12-15% earnings growth, knowing that over time, compounding would do the heavy lifting.
He wasn't chasing alpha. He was underwriting durability.
CRISIL and 3M India: The outsiders
Around the early 2000s, he began adding companies like CRISIL and 3M India. Again, not the kind of names retail investors or even brokerages covered heavily.
CRISIL, at the time, was primarily a credit rating agency, a niche business. But Damani understood that as India's banking and NBFC sector scaled up, so would credit. And wherever credit expanded, rating would become mandatory. This meant CRISIL's revenue was both growing and recurring like a subscription. The costs were low, the moat was regulatory, and the competition was minimal.
3M India, meanwhile, looked like a conglomerate no one could explain. Adhesives, medical devices, car care, Post-it notes, all under one roof. But Damani looked past the complexity and saw the pattern: a premium-pricing business, backed by global IP, in categories where quality mattered more than price. 3M wasn't a volume play, it was a margin play. Again, it ticked the box of low capex, low receivables, and strong brand recall.
HDFC Bank: The 'Pedder Road' of Indian banking
Among Damani's early investments, few were as prescient or as simply explained as HDFC Bank.
At the time he began buying, the bank's market cap was barely Rs 400 crore. It was a fledgling private sector institution in a market dominated by lumbering public sector banks like SBI, which commanded scale, visibility, and retail trust.
Most investors saw HDFC Bank as too small, too new, and too conservative to matter. But Damani saw something else: clean books, a conservative culture, and the DNA of compounding.
When asked why he preferred HDFC Bank over the bigger PSU banks, Damani reportedly gave an answer that became legendary among market insiders:
' Dharavi, Dharavi hota hai… aur Pedder Road, Pedder Road. Aage jaake HDFC Bank ka bhaav dekh lena.' (Dharavi is Dharavi and Pedder Road is Pedder Road… just wait and watch where HDFC Bank ends up.)
He wasn't picking based on size. He was picking based on location and long-term livability, such as quality of assets, not quantity. In his view, PSU banks might have more branches and legacy muscle, but they were weighed down by inefficiencies, political lending, and bad governance. HDFC Bank, by contrast, was small but pristine.
He held the stock for years. And true to form, the market eventually caught up to the value. What started at a Rs 400 crore valuation is now a multi-lakh crore giant, widely regarded as one of the finest private banks in Asia.
DMart: The investor who built the perfect stock
By the early 2000s, Damani had done what most public market investors dream of: He had made his money. But more importantly, he had built his worldview.
He now knew what made a business great: predictable cash flows, pricing power, clean execution, capital efficiency, and most critically, trust. So when he began thinking about his next move, he didn't look at hedge funds or flashy tech bets. He looked at something far more basic: groceries.
And just like that, the investor who had quietly accumulated shares in HDFC Bank and Gillette, who had held on to tobacco and toothpaste, now began setting up his retail chain.
But this wasn't a pivot. It was a natural progression — Damani wasn't abandoning investing. He was now applying it.
He launched DMart in 2002 with two small stores and a decade of research. He had spent the late '90s running Apna Bazaar franchise outlets not for profit, but to learn. He understood inventory turns, vendor margins, and customer psychology. What he saw in those years informed what would become the core of the DMart model.
And, like all his investments, he built it to last.
The investment thesis behind a retail business
If you strip down DMart to its core, you'll find that it runs on the same logic as a value stock Damani would buy:
Don't overpay for assets: DMart owns 90% of its stores. It buys land and avoids leases, knowing that rental inflation can destroy long-term margins.
Don't chase growth for optics: It expands slowly, only when unit economics make sense.
Keep capital allocation clean: It has virtually no debt. Cash flows are reinvested, not squandered.
Prioritise efficiency over aesthetics: No glossy showrooms. Just low costs, faster stock turns, and minimal inventory waste.
Create a moat through trust, not tech: Suppliers trust DMart to pay on time. Customers trust it to offer the lowest prices. That flywheel beats any fancy app.
In short, he built DMart like he would invest in it.
And the results speak for themselves. In a sector where everyone else burned cash, DMart made money.
When Avenue Supermarts listed in 2017, it wasn't just the biggest retail IPO in Indian history. It was the ultimate validation of his approach: the investor had built a business that even he would struggle to buy at a fair price today.
VST and India Cements: Two sides of the same Damani coin
Not every Damani investment is a household name like DMart. Some of his most powerful lessons lie hidden in two unassuming, old-economy businesses: VST Industries and India Cements. Both were out of favour when he bought them. But to Damani, they offered what he values most: asymmetry – limited downside, and the possibility of outsized long-term returns.
VST Industries: The dividend machine that everyone ignored
In 2000, cigarette stocks were unloved. The industry faced regulatory overhangs, social backlash, and rising taxes. Institutional investors avoided it. The media ignored it. And retail had no interest in a company that didn't 'grow.'
But Damani didn't buy VST for growth. He bought it for cash flow.
VST, a Hyderabad -based maker of regional cigarette brands, had three things going for it:
Steady volume sales in its core market
High margins, thanks to pricing power and low competition
And most importantly, an 8-10% dividend yield at the time
It had zero debt, limited capex needs, and a parent in British American Tobacco (BAT). Most saw stagnation. Damani saw predictability.
And when a takeover battle broke out between Damani and ITC (reportedly with tacit support from BAT), the stock briefly became front-page news. Damani tried acquiring a controlling stake through an open offer. He didn't succeed. But he walked away with a 20%+ stake in the company.
Then he did what very few investors do after a failed control play: he held on. For over two decades.
The result:
VST's dividend income alone more than paid for the stake.
The stock went from under Rs 100 to over Rs 3,000.
Damani's stake compounded quietly to over Rs 1,000 crore — all without him ever running the business.
VST was classic Damani: no hype, no rush — just quality, mispriced.
India Cements: When he played the cycle, then walked away
Fast forward to 2019.
The cement sector was in trouble. Demand was sluggish, capacity was underutilised, and India Cements, a once-formidable South India player, was struggling under debt and falling margins. Most investors were staying away.
Damani, however, started buying. Quietly, and then aggressively. By mid-2020, as Covid crashed markets, he owned over 20% of India Cements.
Why? Because even in its worst years, India Cements had real assets — functioning plants, limestone reserves, and physical infrastructure that would cost multiples to rebuild. More importantly, Damani knew that cement is a cycle. And when capacity tightens, prices jump. Operating leverage kicks in. Margins swell.
He wasn't betting on a turnaround led by management brilliance. He was betting on mean reversion, asset value, and the chance that someone bigger might want in.
And that's exactly what happened.
In mid-2024, after holding the stock for just over four years, Damani sold his entire 23% stake, not to retail, not on the open market, but in a strategic block deal to UltraTech Cement, India's largest player.
Estimated exit value: Rs 1,900 crore+
Damani had turned a deep-value, low-visibility asset into a blockbuster special situation – timed entry, quiet accumulation, and a clean, premium exit to a strategic buyer.
India Cements showed another side of Damani — the opportunist who doesn't need permanence, just clarity.
What retail investors can learn from Damani
Look closely at the way Damani's built wealth across public markets, real estate, and consumer retail, and you'll find a surprisingly replicable blueprint.
Not in scale. But in principle.
Whether it was buying Gillette in the '90s, HDFC Bank in its infancy, holding VST Industries for over two decades, spotting the asset value in India Cements, or building DMart from the ground up. His decisions followed the same compass: clarity over complexity, patience over panic, and quality over narrative.
Here's what stands out:
1. Buy simplicity, not sophistication
Damani didn't bet on moonshots. He bet on toothpaste, cement, savings accounts, and groceries — categories with deep demand and shallow hype. He understood that businesses serving basic human needs tend to endure, and that endurance matters more than excitement when it comes to compounding.
2. Invest like an owner — even if you're not one
He studied businesses like an insider. He held them like a promoter. In VST, he collected dividends like he ran the treasury. In India Cements, he read the cycle like an industry veteran. Even before launching DMart, he ran Apna Bazaar franchises, just to learn. That owner mindset is what gave him the conviction to hold when markets moved on.
3. Size up when the odds are tilted
Damani doesn't take 0.3% positions in his high-conviction bets. He owns 67% of DMart. He owned over 20% in VST and India Cements. But these bets came after years of thought, research, and price discipline. He reminds us that concentration without preparation is gambling but with preparation, it becomes focus.
4. Let compounding work — Don't interrupt it
The real secret in Damani's style isn't stock picking. It's holding. He sat on the winners long past the first 2x. He gave businesses the time to prove his thesis right — and to let time multiply the returns.
5. Exit without emotion
When the thesis broke, he walked. Quietly. No averaging down, no press conferences. That was true with some of his PSU bets, and it was true when he sold India Cements to UltraTech. For him, an exit isn't a mistake, it's just a completed bet. The clarity to leave is as important as the conviction to enter.
He didn't just buy stocks. He understood businesses. And then perhaps more importantly, he waited. Because the secret to getting rich in markets isn't just knowing what to buy. It's knowing what to hold, what to avoid, and how long you're willing to sit with clarity while the rest of the world panics.
That's the Damani blueprint. And for investors willing to learn, it's quietly revolutionary.
Note: This article relies on data from the annual report and industry reports. We have used our assumptions for forecasting.
Parth Parikh has over a decade of experience in finance and research and currently heads the growth and content vertical at Finsire. He holds an FRM Charter along with an MBA in Finance from Narsee Monjee Institute of Management Studies.
Disclosure: The writer and his dependents do not hold the stocks discussed in this article.
The website managers, its employee(s), and contributors/writers/authors of articles have or may have an outstanding buy or sell position or holding in the securities, options on securities or other related investments of issuers and/or companies discussed therein. The content of the articles and the interpretation of data are solely the personal views of the contributors/ writers/authors. Investors must make their own investment decisions based on their specific objectives, resources and only after consulting such independent advisors as may be necessary.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hans India
28 minutes ago
- Hans India
ED restores assets worth Rs 3.82 crore to Waqf Board
Bengaluru: In a significant move to restore the Proceeds of Crime (POC) to the rightful claimants, the Enforcement Directorate (ED), Bengaluru Zonal Office, has taken a significant step by releasing properties valued at Rs 3.82 crore to the Karnataka Waqf Board in a money laundering case. The money from the Waqf Board released for fixed deposits was utilised to purchase a Mercedes-Benz car, and a further amount was transferred to a trading corporation. According to an official statement of the ED issued on Tuesday, the agency initiated an investigation on the basis of an FIR filed against two Vijaya Bank officials and Syed Siraj Ahmed, a First Division Assistant with the Waqf Board. In this case, the Waqf Board issued two cheques amounting to Rs 4,00,45,465 to open Fixed Deposit accounts at Vijaya Bank. However, instead of opening the fixed deposits, the money was siphoned off by transferring it to fictitious entities, the ED stated. Further, Rs 4 crore was transferred to M/s. Verkeys Realities Pvt Ltd, which spent Rs 1.10 crore purchasing a Mercedes car from Ghatge Motors Pvt Ltd. Further, Rs 2,72,74,444 was transferred back to the account of M/s. Ajay Sharma Trading Corporation, the ED stated. Upon uncovering these illicit financial transactions and the proper money trail of Proceeds of Crime (POC), the ED issued a Provisional Attachment Order (PAO) totalling Rs 3,82,74,444, the ED said. On March 31, 2017, ED filed a Prosecution Complaint (PC) before the Special PMLA Court in Bengaluru, against six individuals and entities, including M/s. Verkeys Realities Pvt Ltd, the statement said. In line with the PMLA and its core objective of ensuring the restitution of POC to the legitimate victims, the ED did not raise any objections when the Additional Sessions Judge considered the release of the funds to the Karnataka State Wakf Board—the rightful claimant in this case, the ED said. On July 1, 2025, in a further demonstration of its commitment to justice, ED facilitated the release of the entire amount. A banker's cheque of Rs 3,82,74,444 was handed over to Jeelani H. Mokashi, CEO (Additional Charge), of the Karnataka State Wakf Board, the ED said. This marks a significant step forward in the ED's ongoing mission to restore the misappropriated funds to those who have been wronged, the ED said. This release underscores the ED's commitment to ensuring justice for victims of financial crimes. ED remains resolute in its dedication to combating money laundering and ensuring that the Proceeds of Crime are returned to their rightful owners, the ED stated.
&w=3840&q=100)

Business Standard
30 minutes ago
- Business Standard
What's firing up Bharat Dynamics? 8 reasons behind MOFSL's positive view
MOFSL on Bharat Dynamics: Ammunition and missile systems manufacturers Bharat Dynamics Limited (BDL) shares were in focus on Thursday, July 10, 2025 after Motilal Oswal Financial Services (MOFSL) initiated coverage on the stock. On the bourses, however, Bharat Dynamics' share price fell 2.53 per cent to an intraday low of ₹1,934.80. Around 9:50 AM, the Bharat Dynamics share was trading 1.60 per cent lower at ₹1,953.30 per share, while the benchmark BSE Sensex was down 0.12 per cent at 83,434.31 levels. MOFSL today initiated coverage on Bharat Dynamics with a 'Neutral' rating and a target price of ₹1,900, indicating a downside of 4 per cent from current levels. 'The stock currently trades at 70x/52x/38x P/E on FY26/27/FY28 estimates. We initiate coverage on the stock with a 'Neutral' rating and a target price (TP) of ₹1,900 based on 42x September'27E P/E,' Teena Virmani and Prerit Jain, research analysts at MOFSL said, in a note dated July 10. Motilal Oswal analysts said that they like Bharat Dynamics' business model and strong growth potential but would prefer lower entry points given current valuations. They also flagged risks including any potential cut or reprioritisation in India's defence budget, contract cancellations or failures, changing procurement rules, and supply chain disruptions. Meanwhile, here are the 8 key reasons behind MOFSL's coverage initiation: Rising global spend boosts Indian defence According to MOFSL, NATO's recent commitment to raise defence spending to 5 per cent of GDP by CY35 has strengthened the outlook for global defence players, with indirect positive implications for India. This, analysts believe, could lead to India boosting its own defence budget and create new export opportunities for domestic players. Additionally, India's own emergency procurement drive and the Defence Acquisition Council's (DAC) recent approvals worth ₹1 trillion are expected to considerably expand the addressable market for companies like BDL. Positive industry tailwinds The company's estimated addressable market size is around ₹50,000 crore, driven by missile procurements across platforms including submarines (Project 75I), fighter jets (LCA Tejas Mk1A, Su-30MKI), and helicopters (LCH Prachand, ALH Dhruv). Continued demand for systems like QRSAM, MRSAM, NAG, and VSHORAD, alongside existing long-term contracts for high-value imports like S-400 and Barak-8, analysts highlighted, are expected to fuel growth. Export demand, especially for Akash missile systems, will also support order inflow. Emerging as a leading integrator of missile platforms MOFSL said Bharat Dynamics has transformed from a missile manufacturer into an end-to-end weapon systems integrator for the Army, Navy, and Air Force. It is expanding into drone-delivered payloads, guided bombs, warhead and engine manufacturing, and other segments such as mines and propellants. The company is actively exploring new partnerships with foreign original equipment manufacturers (OEMs) and continues to work closely with DRDO on a range of high-impact defence programs. Strong order book, easing supply chain issues to scale up revenue As of FY25-end, the missile maker's order book stood at ₹22,700 crore, registering a healthy compound annual growth rate (CAGR) of 27 per cent over FY20–24, driven by large deals related to Akash, Konkur, and exports. While supply chain bottlenecks due to the Russia-Ukraine conflict and regional geopolitical tensions in Israel had earlier impacted revenue conversion, MOFSL noted that these issues have begun to ease. With execution expected to normalise, the company is now projected to deliver a 35 per cent revenue CAGR over FY25–28. Focus on indigenisation Bharat Dynamics has been consistently localising its platforms, with import dependence falling majorly over the years. The company now achieves 80–90 per cent indigenisation on several missile systems, which boosts its ability to compete independently in domestic tenders. As a key development partner to DRDO for about 40 projects, BDL is well-positioned to capitalise on indigenous defence production as more projects move into the manufacturing phase. Continuous capacity growth, research efforts to minimise reliance on imports The company has expanded its in-house production capabilities with new facilities like the integrated Radio Frequency Seeker Unit at Kanchanbagh, aimed at producing and testing critical missile components. It is also increasing its capacity to manufacture next-gen SAMs, VSHORAD rockets, ATGM propellants, and more. R&D spending has risen sharply over the past two years, with ongoing efforts in both new product development and upgrading legacy systems to meet emerging operational requirements. Boosting exports BDL's export momentum has picked up sharply following government approvals for Akash system exports to nine countries. Export revenues rose to ₹1,200 crore in FY25 from ₹160 crore in FY24. The company's growing global portfolio includes Akash (SAM), Astra (Air-to-Air), Helina (Air-to-Surface), anti-airfield weapons, various torpedoes, and anti-tank missiles such as Konkurs-M and Milan-2T. Lightweight torpedoes have already been exported, and other products are seeing increasing interest globally. Strong financial outlook MOFSL projects a 35 per cent revenue CAGR and 51 per cent PAT CAGR for BDL over FY25–28, driven by improved execution and easing supply chain margins are expected to strengthen from 23.8 per cent in FY26 to 25.5 per cent by FY28, aided by indigenisation and lower provisioning. With a steady capex of ₹200–300 crore annually and efficient working capital management, the company's return on equity (RoE) and return on capital employed (RoCE) are projected to rise to 25.2 per cent and 25.6 per cent, respectively, by FY28.
&w=3840&q=100)

Business Standard
30 minutes ago
- Business Standard
Thinking of investing in Anthem Biosciences IPO? Know key risks, strengths
Anthem Biosciences IPO: Contract research, development, and manufacturing organisation (CRDMO) Anthem Biosciences is set to launch its Initial Public Offering (IPO) on Monday, July 14, 2025. The public issue is entirely an Offer for Sale (OFS), with promoters and existing shareholders divesting up to 59.6 million equity shares, aggregating to approximately ₹3,395 crore. The public issue is entirely an Offer for Sale (OFS), with promoters and existing shareholders divesting up to 59.6 million equity shares, aggregating to approximately ₹3,395 crore. From the promoter group, Ganesh Sambasivam and K Ravindra Chandrappa are among those participating in the OFS. Viridity Tone LLP, Portsmouth Technologies LLC, and Malay J. Barua are among the shareholders divesting their stakes through the Anthem Biosciences IPO. Anthem Biosciences has set the price band for the IPO at ₹540 to ₹570 per share. The minimum application size has been set at 26 shares per lot. The issue will open for subscription on July 14 and remain available until July 16. The company's shares are tentatively scheduled to make their D-Street debut on July 21, 2025. It is worth noting that Anthem Biosciences will not receive any proceeds from the IPO. All the funds raised will go directly to the selling shareholders, after accounting for offer-related expenses and applicable taxes, which will be borne by the respective sellers. As investors await the opening of Anthem Biosciences IPO, here are the key strengths and risks outlined in its Red Herring Prospectus (RHP) that every investor should be aware of: Key strengths of Anthem Biosciences Strong global customer base with long-term relationships: As of March 31, 2025, Anthem Biosciences had more than 550 customers across both its CRDMO and specialty ingredients businesses, spread over more than 44 countries, including the United States, European countries, and Japan. Many of these customers have long-standing relationships with the company. According to the F&S Report, Anthem Biosciences has the highest number of customers among its assessed Indian peers as of March 2025. Market-leading fermentation capacity: The company has the largest fermentation capacity among Indian CRDMO companies, with a 142 kL capacity as of March 31, 2025. Following the completion of its expansion activities by the first half of Fiscal 2026, Anthem Biosciences' fermentation capacity is expected to reach 182 kL—more than six times the fermentation capacity of the second-largest assessed player in the industry, according to the F&S Report. Diversified specialty ingredients portfolio: Anthem Biosciences also maintains a wide specialty ingredients portfolio and is well-positioned to capitalise on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products, probiotics, enzymes, nutritional actives, vitamin analogues, and biosimilars. Focused business model for emerging pharma and biotech players: According to the F&S Report, while large multinational pharmaceutical companies currently dominate the global pharmaceuticals market, there is a growing prominence of small pharmaceutical and biotech companies, reflecting a broader shift in the pharmaceutical industry towards novel therapies and innovation-driven growth. Anthem Biosciences has a differentiated business model catering to the needs of small pharmaceutical and emerging biotech companies, from discovery to commercial manufacturing. Comprehensive end-to-end service capabilities: Anthem Biosciences offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development, and manufacturing) for both small molecules and biologics and is the fastest-growing Indian CRDMO. Key risks of Anthem Biosciences High dependence on CRDMO services: Anthem Biosciences' business depends on the demand for its contract research, development and manufacturing organisation (CRDMO) services, which contributed to 81.65 per cent of its revenue from operations in Fiscal 2025. Any adverse impact on its CRDMO customers' business or the industries in which they operate may have a material adverse effect on the company's business. Dependence on DavosPharma for US market presence: Anthem Biosciences is dependent on its arrangements with DavosPharma, the affiliate of one of its shareholders and also a selling shareholder, for its business and marketing activities in the United States. Reliance on the success of specific molecules: The company's financial performance is dependent on the success of the molecules it manufactures, and its revenue from operations decreased in Fiscal 2023 compared to Fiscal 2022, partly attributable to the failure of a Phase III molecule and the withdrawal of a commercialised molecule. Accordingly, any unfavorable developments affecting these molecules' success rates, including failures to obtain the required regulatory approvals or withdrawal of commercialised molecules, may have an adverse impact on Anthem Biosciences' business, financial condition, results of operations, and prospects. Risks associated with project failures: Developmental and commercial manufacturing contributed to 70.78 per cent of Anthem Biosciences' revenue from operations and 71.90 per cent of its total number of projects in Fiscal 2025. The company's business may be adversely affected by a failure in early-phase developmental projects or a failure to develop or manufacture commercially viable drugs, including for reasons that are not within Anthem Biosciences' control.